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BACKGROUND: A side effect of diagnostic needle biopsies is the possibility to disseminate tumour cells into the needle track, which may
cause concern in certain malignant tumour types.
METHODS: In order to prevent tumour cell dissemination we developed a technology that uses radiofrequency (RF) pulses to sterilise
the needle track and denaturate tumour cells. To determine feasibility, we applied this technology to fine needle aspiration biopsy
(FNAB) and used breast cancer as a model tumour. Routine FNAB was performed in 88 patients with adenocarcinoma and blood
droplets passing the skin orifice were cytomorphologically analysed for the presence of tumour cells.
RESULTS: The analysis showed the presence of tumour cells in 65/88 cases (74%). When using an experimental anti-seeding device in a
subset of patients viable tumour cells were found in 0/31 cases (Po0.001). In all 31 patients blood passing the skin orifice was sparse.
No degrading effect on the cytological sample inside the needle was detected and pain caused by the RF pulses was comparable to
that of the biopsy procedure itself.
CONCLUSION: The herein presented method has the potential to prevent the dissemination of viable tumour cells in the needle track
and minimize bleeding without additional pain or degradation of the aspirate.
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In order to achieve a conclusive diagnosis regarding malignancy in
suspicious lesions it is compulsory in the vast majority of
situations to perform diagnostic needle biopsies or diagnostic
surgery. Concerning diagnostic needle biopsies there are a variety
of methods and procedures used which can be subdivided into fine
needle aspiration biopsy (FNAB) and core needle biopsy (CNB).
Fine needle aspiration biopsy results in samples consisting of
single cells and/or minor cell complexes and tissue fragments,
whereas CNB results in cut or punched tissue blocks of various
volumes. The equipment and methodology to acquire samples are
very different for these two methods. The outer diameter of a
common FNA needle is in the range of 0.5–0.8mm, whereas a CNB
needle is in the range of 1.2–3mm or more. Histological tissue
sampled by means of CNB procedures significantly facilitates
morphology-based diagnostic decision making, including the
important discrimination between in situ and invasive tumour
growth. However, this diagnostic advantage is associated with a
higher risk of side effects. Numerous case reports of malignant
seeding resulting from needle biopsies have been reported for
different tumours (Boutin et al, 1995; Herts and Baker, 1995; Jones
et al, 2005; Vaghefi et al, 2005; Al-Leswas et al, 2008) and increasing
caution is observed in highly aggressive malignancies, for example
in the pancreas (Micames et al, 2003). The true incidence of tumour
cell dissemination is hard to determine. This can in part be
explained by the fact that it is rather difficult to trace biopsy-
induced tumour cell dissemination in surgically removed organs or
excised tissue containing the entire or only parts of the needle
tracks. Moreover, it may take several years for the disseminated and
surviving tumour cells to reach the size of clinically detectable local
or peripheral growth. This is further complicated by the fact that the
occurrence of needle biopsy-induced local or distant tumour cell
growth generally cannot be distinguished from spontaneous tumour
recurrence and that post-operative treatment with radiotherapy
(Thurfjell et al, 2000) and/or drugs may inhibit spontaneous, as well
as biopsy–induced, relapse.
In the present article we report on a technology that is able to
denature tumour cells in the needle track after needle biopsies. For
this feasibility study we chose breast cancer as a model tumour as
it showed favourable characteristics when trying to study local
seeding. Blood coming from the skin orifice after final retraction of
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sthe biopsy needle can be conveniently sampled and analysed for
the presence of tumour cells. As FNAB is the standard method of
action regarding needle biopsies in breast lesions in Scandinavia,
we applied the anti-seeding technology to FNAB procedures.
MATERIALS AND METHODS
Patients
This study was approved by the local ethics committee and
included 88 patients with adenocarcinomas in the breast diagnosed
by FNAB. The first part of the study aimed at establishing breast
cancer as a model for tumour cell dissemination. For this purpose
routine FNAB procedures were performed in 57 patients at clinical
centre 1. Subsequently 31 patients in clinical centre 2 underwent
routine FNAB procedure followed by a second needle biopsy using
the anti-seeding device. Patient data are shown in Table 1. All
patients were diagnosed according to standard hospital protocols
and had a confirmed invasive adenocarcinoma as determined by
post-surgical histopathology.
Anti-seeding instrumentation
The anti-seeding device consists of a control console, as well as a
specially designed anti-seeding needle. The needle has an
electrically insulated shaft, a length of 50mm or 80mm and an
outer diameter of 0.7mm. The bare tip, including the bevel section
has a length of approximately 6mm. Energy is delivered in a
computer-controlled regime (voltage/current controlled) and
triggered by the operator’s needle movements by means of a
miniaturised accelerometer. The applied symmetrical burst pulses
have a 55ms linear ramp, a duration of 200ms and a radio-
frequency (RF) period of 3.3ms. Every burst pulse incorporates
around 60000 periods and delivers an energy of approximately 6J.
Consecutive burst pulses are separated by a minimum time
interval. Additionally, pulses are blocked if the velocity of the
needle is too low in order to ensure sufficient heat conduction. The
tissue cell sample, which is protected by the Faraday’s cage realized
by the needle internal channel cavity, is thus fully protected from
heat degradation. Skin burn is avoided by blocking energy pulses
in proximity to the skin orifice. The entire prototype, including the
needle, was designed by NeoDynamics, Sweden, under the lead of
HW The device is conform to the international safety norm EN
60601-1. It meets the insulation demands of cardiac floating
regarding patient applied parts, that is, a frequency weighted
patient leakage current of less or equal to 10mA, which is lower
than that required to disturb the cardiac activity even in direct
contact.
Biopsy protocol
In 57 patients at the clinical centre 1 diagnostic FNAB procedures
were performed by two experienced cytologists (GA and P-OS)
using needles with an outer diameter of 0.7mm (Sterican, B. Braun
AG). Fine needle aspiration biopsy was performed without local
anaesthesia and without ultrasound guidance. The needle was
mounted on a standard syringe hand-piece (Cameco, Medical Lth.,
Great Britain, UK). After entering the tumour the needle passed the
mass 10–15 times in various directions in order to collect
representative material from the entire tumour mass. In 31
patients at clinical centre 2 ultrasound-guided FNAB was
performed by an experienced radiologist (MJ). The lesions were
detected using an US instrument (Philips iU22). While performing
the biopsy, the radiologist held the needle at the base while it was
connected with flexible tubing to the syringe, manoeuvred by a
technician. Around 10 to 15 passes through the lesion were
performed in order to acquire a sufficiently high sampling yield.
In these 31 patients a subsequent biopsy procedure was performed
incorporating the anti-seeding device. The needle was inserted
through the skin at a different location than the previous FNAB
procedure. While the needle was passed through the lesion back
and forth, as well as finally retracted, burst pulses were applied.
Immediately after the biopsy procedure blood/secretion droplets
emerging from the skin orifice were sampled on a glass slide. The
samples were air-dried, May-Gru ¨nwald-Giemsa stained and
microscopically analysed by two experienced cytologists
(GA and P-OS).
RESULTS
The results following FNAB procedures with and without the anti-
seeding device are shown in Table 2. Seeding frequencies in
standard FNAB procedures at the two clinical centres did not differ
significantly (Fisher’s exact test, two-sided, P¼0.4466). In total,
tumour cells in the blood droplet/s were present in 65 of the
88 cases analysed at the two centres (74%). Breast cancer showed
to be an adequate model tumour for studying local seeding. Blood
passing the skin orifice could easily be sampled and analysed.
Protocols from clinical centre 1 were adopted for the study at
centre 2. Fine needle aspiration biopsy procedures using the anti-
seeding needle were performed in 31 cases at clinical centre 2
without complications. Induced pain was comparable to that of
routine fine needle aspiration procedures. The acquired aspirate
showed no sign of degradation. As shown in Figure 1, the RF burst
pulses could be detected on the US image. Bleeding was
significantly reduced as compared with common FNAB. By
applying light mechanical pressure to the breast, secretion was
extracted from the needle track. Tumour cells in the secretion were
found in only 1 of 31 cases (3%) after anti-seeding needle
performance, (McNemar’s test, two sided, Po0.001). None of the
tumour cells in the solitary positive sample after the anti-seeding
needle biopsy were judged to be morphologically well preserved.
Table 1 Clinical and histopathological data on patients included in
the study
Clinical Centre 1 Clinical Centre 2
No. of patients 57 31
Tumour size (mm) 23.7±13.1 (s.d.) 17.0 ± 7.8 (s.d.)
Histological type No. % No. %
Ductal 43 75 26 84
Lobular 12 21 4 13
Others 2 4 1 3
Malignancy grade (Elston) No % No %
I 246 1 9
II 35 61 21 68
III 20 35 4 13
Table 2 Presence of tumour cells in sampled blood droplets/secretion






FNAB with anti-seeding 31 3
a
Abbreviation: FNAB¼fine needle aspiration biopsy.
aCytomorphologically degener-
ated tumour cells (see Figure 4).
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Cytological analysis of the aspirate after FNAB with anti-seeding
showed that the sample was not distinguishable from an aspirate
acquired by standard FNAB (Figure 2). Analysis of the blood
droplet/s after common FNAB showed different levels of tumour
cell concentrations. The aim of this study, however, was not to
quantify tumour cell concentration. Figure 3 shows a smear of a
sampled blood droplet after standard FNAB. The cytological
analysis of the secretion after FNAB with anti-seeding showed a
significantly reduced number of erythrocytes and one case
presenting tumour cells that were judged cytomorphologically
degenerated (Figure 4).
DISCUSSION
Today the battle against malignant diseases is focused on early
diagnosis and treatment. When a malignant disease is diagnosed,
the next step is to determine histopathological characterisation
and malignancy potential, clinical stage, as well as an increasing
number of biological tumour markers. On the basis of the results
of these investigations a decision is made concerning treatment
that can be of local and/or general mode, depending on
morphological characteristics, the spread of disease and biological
markers. In order to obtain a conclusive diagnosis it is generally
accepted to use invasive cell- or tissue-sampling methods, that is,
FNAB, CNB or surgical biopsy. Dissemination of tumour cells
during biopsies is a recognised complication of these procedures
and a cause of concern in certain aggressive tumour forms
(Micames et al, 2003; Rodgers et al, 2003). However, its true
incidence and clinical significance is hard to determine. In the
literature, prophylactic measures against needle track seeding
include surgical resection (Intra et al, 2005), radiotherapy
(Espinoza et al, 2005) and cauterisation of the needle tract (Liang
et al, 2009). However, surgery and radiotherapy are rarely feasible
being both costly and time intensive. Cauterisation of the needle
track has been reported for treatment electrodes used in
therapeutic modalities applying RF and microwave ablation,
in which the treatment electrode is being retracted while still
active (Murakami et al, 1995; Buscarini and Buscarini, 2004;
Wiksell et al, 2010).
We herein present a lean and patient-friendly technology that
diminishes the risk of tumour cell seeding when performing needle
biopsy procedures. To our knowledge this new technique for the
first time combines diagnosis with local minimal treatment
Figure 2 May-Gru ¨nwald-Giemsa-stained fine needle aspirate from a
breast adenocarcinoma using the anti-seeding technique. The cellular
material is well preserved and can be analysed according to generally used
cytological criteria (magnification  20).
Figure 3 May-Gru ¨nwald-Giemsa-stained smear of a blood droplet that
passed the skin orifice after retraction of the FNA needle from a breast
adenocarcinoma without using the anti-seeding technique. Well-preserved
cancer cells (arrows) can be seen surrounded by peripheral blood cells
(magnification  20).
Figure 4 May-Gru ¨nwald-Giemsa-stained smear of a droplet of fluid that
passed the skin orifice after retraction of the FNA needle from a breast
adenocarcinoma using the anti-seeding technique. Only a minor number of
blood cells and denatured cancer cells (arrow) can be seen (magnification
 20).
Figure 1 US image taken during FNAB with anti-seeding. The tumour
mass can be seen in the centre with the needle entering from top right. The
anti-seeding pulse shows on the image as a short flash (arrow).
Prevention of tumour cell dissemination
H Wiksell et al
1708




















spreventing tumour cell dissemination by means of RF burst pulses.
The aspirate inside the needle is not degraded because of the
sample being protected within the Faraday’s cage realized by the
needle cavity. Furthermore the movement of the needle provides
forced cooling to the sample inside, following needle exposure to
dissipatively heated tissues. The anti-seeding procedure was safe
and resulted in no complications for the patient. Tumour cells that
were disseminated into the needle track were denatured and
bleeding was significantly reduced. Using the breast tumour as a
model in this feasibility study proved to be suitable. For standard
fine needle procedures, the blood droplet/s passing the skin orifice
were easily sampled and analysed. As the anti-seeding procedure
reduced the amount of blood in the needle channel, bleeding was
reduced and a light mechanical pressure had to be applied in order
to obtain fluid from inside the needle channel. As no well-
preserved tumour cells were present in the secretion that passed
the skin orifice, it is reasonable to assume that they were denatured
in the needle track. This is further underlined by the denatured
tumour cells found in one solitary case. The reason that needle
biopsy procedures with anti-seeding were performed after
common FNAB is because of the ethical considerations that aimed
at securing a FNAB sample before applying the new technology.
However, as different needle biopsy locations were used this does
not constitute a weakness of the study that aimed at establishing
feasibility. Radiofrequency pulses applied inside the tumour and
the associated reduction of bleeding could possibly have effects on
the dissemination of tumour cells into blood and lymphatic
vessels. The presented technology has the potential to denature
cancer cells in the needle track without affecting the aspiration
sample or causing additional pain to the patient. The data obtained
herein motivates a randomized clinical trial with long-term follow-
up comprising highly aggressive malignancies in which tumour
spread is a well-known major complication. The technology can
hopefully be applied to other needle biopsy modalities, such as the
widely used CNB and contribute to improve the safety of needle-
based diagnostics.
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